ArticleEnvironmental science & technology2023
Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate.
Article in Environmental science & technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Managing infectious aerosols to counter engineered pandemics: Current recommendations and future research.Risk analysis : an official publication of the Society for Risk Analysis · 2025Guideline
- Inactivation of airborne pathogen surrogates by triethylene glycol.Applied and environmental microbiology · 2026Article
- Validation of digital PCR as a complementary tool to MS2 plaque assay for virucidal activity assessment.Frontiers in public health · 2026Article
- Glycol vapor pathogen disinfection: a defensive technology for emerging biothreats.Frontiers in microbiology · 2026Review
- An Assessment of the Efficacy of Commercial Air Ionizer Systems Against a SARS-CoV-2 Surrogate.Microorganisms · 2025Article
- Rapid virucidal activity of an air sanitizer against aerosolized MS2 and Phi6 phage surrogates for non-enveloped and enveloped vertebrate viruses, including SARS-CoV-2.Applied and environmental microbiology · 2025Article
- The activity of indigo carmine against bacteriophages: an edible antiphage agent.Applied microbiology and biotechnology · 2025Article
- Copper Oxide Electrochemical Deposition to Create Antiviral and Antibacterial Nanocoatings.Langmuir : the ACS journal of surfaces and colloids · 2024Article
- Impact of test methodology on the efficacy of triethylene glycol (Grignard Pure) against bacteriophage MS2.Aerosol science and technology : the journal of the American Association for Aerosol Research · 2023Article
- Non-Pharmacological Strategies and Interventions for Effective COVID-19 Control: A Narrative Review.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical" by the US EPA. GP has already received approval from the US EPA under its Section 18 Public Health Emergency Exemption program for use in seven states. This study characterizes the efficacy of GP for inactivating MS2 bacteriophage─a nonenveloped virus widely used as a surrogate for SARS-CoV-2. Experiments measured the decrease in airborne viable MS2 concentration in the presence of different concentrations of GP from 60 to 90 min, accounting for both natural die-off and settling of MS2. Experiments were conducted both by introducing GP aerosol into air containing MS2 and by introducing airborne MS2 into air containing GP aerosol. GP is consistently able to rapidly reduce viable MS2 bacteriophage concentration by 2-3 logs at GP concentrations of 0.04-0.5 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.